Protagonist Therapeutics Inc (PTGX)
Profitability ratios
Return on sales
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Gross profit margin | 100.00% | 100.00% | 100.00% | 89.86% | 100.00% |
| Operating profit margin | 58.20% | -156.09% | -494.24% | -460.01% | -225.36% |
| Pretax margin | 64.32% | -131.59% | -479.26% | -458.94% | -226.51% |
| Net profit margin | 63.34% | -131.59% | -464.29% | -448.25% | -231.07% |
Protagonist Therapeutics Inc's profitability ratios exhibit varying trends over the analyzed period. The gross profit margin has shown resilience, maintaining a consistently high level, withstanding at 89.86% in 2021 and reaching 100.00% in subsequent years. This indicates the company's ability to effectively manage its production costs and generate value from its core operations.
However, the operating profit margin, while improving significantly from negative figures in 2021 and 2022, continued to face challenges in the following years. Despite a remarkable recovery to 58.20% in 2024, the company needs to further enhance its operational efficiency to sustain positive margins.
Similarly, the pretax and net profit margins also depicted a recovery trend, turning positive in 2024 after posting negative values in previous years. The positive trend indicates the company's efforts in controlling expenses and improving revenue generation. Overall, Protagonist Therapeutics Inc has shown positive momentum in enhancing its profitability, albeit further efforts may be required to ensure sustained growth.
Return on investment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 33.95% | -26.16% | -52.99% | -36.19% | -19.88% |
| Return on assets (ROA) | 36.95% | -22.06% | -49.78% | -35.27% | -20.39% |
| Return on total capital | 0.00% | -27.82% | — | — | — |
| Return on equity (ROE) | 40.75% | -23.45% | — | — | — |
Protagonist Therapeutics Inc's profitability ratios exhibit fluctuating trends over the years.
1. Operating return on assets (Operating ROA) has shown a downward trend from -19.88% in 2020 to -52.99% in 2022, indicating declining operational efficiency in utilizing its assets. However, there was a significant improvement in 2024 to 33.95%, signaling a possible turnaround in asset management.
2. Return on assets (ROA) also displayed a similar pattern, decreasing from -20.39% in 2020 to -49.78% in 2022, before rebounding positively to 36.95% in 2024. This improvement suggests that the company has been able to generate better returns relative to its total assets in the most recent period.
3. Return on total capital was not available for 2020 and 2021 but showed a negative return of -27.82% in 2023. This indicates that the company's overall capital utilization efficiency was not optimal. However, the return improved to 0.00% in 2024, possibly reflecting a more effective capital deployment strategy.
4. Return on equity (ROE) data was also missing for 2020 and 2021, but the ratio was negative at -23.45% in 2023, suggesting a suboptimal performance in generating profits from shareholders' equity. The ROE then significantly increased to 40.75% in 2024, indicating a substantial enhancement in profitability with respect to shareholder investments.
Overall, Protagonist Therapeutics Inc has experienced varying profitability levels in recent years, with improvements in some ratios indicating potential operational and financial efficiency enhancements. However, the company should continue to monitor and optimize its asset and capital utilization to sustain and further enhance its profitability levels.